- Karyopharm Therapeutics reported their Q3 earnings with a beat on revenue and a slight miss on EPS. The company revealed that XPOVIO is making inroads into multiple myeloma.
- Despite the encouraging earnings, the ticker has been sucked into the small-cap sell-off. I am looking to take advantage of the discounted share price and reload my KPTI position.
- I will review the company's Q3 earnings and will also highlight points that help bolster investor sentiment. In addition, I reveal my plans for accumulating KPTI as we leave 2021.
For further details see:
Karyopharm Therapeutics: Unjustified Sell-Off Provides An Opportunity To Reload My Position